PubMed · 2017 · 147 citations · 10 references
Open access
MedicineGeneticsHematologyCytogeneticsEpigeneticsMolecular OncologyBone Marrow PathologyChromosome AberrationsClinical CytogeneticsHematologic MalignanciesMolecular CytogeneticsPediatric HematopathologyClinical HeterogeneityCytogenetic AberrationsCytogenetic AbnormalitiesCytogenetic Prognostic MarkersCytogenetic Risk StratificationCytogenetics In Hematologic DiseaseIncidence RateStratification
Acute myeloid leukemia (AML) is a group of hematological diseases, phenotypic and genetically heterogeneous, characterized by abnormal accumulation of blast cells in the bone marrows and peripheral blood. Its incidence rate is approximately 1.5 per 100,000 in infants younger than 1 year of age and 25 per 100,000 persons in octogenarians. Traditionally, cytogenetic markers are used to stratify patients in three risk categories: favorable, intermediate and unfavorable. However, the forecast stratification and the treatment decision for patients with normal karyotype shows difficulties due to the high clinical heterogeneity. The identification of several genetic mutations additional to classical molecular markers has been useful in identifying new entities. Nowadays, many different mutations and epigenetic aberrations have been implicated in the diagnostic, prognostic and treatment of AML. This review is focused on describing the most important molecular markers with implications for clinical practice.
10
Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations
Roel G.W. Verhaak, Chantal S. Goudswaard, Wim van Putten et al. · Blood · 2005 · 617 citations · Full text
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
James Griffith, James Black, Carlos H. Faerman et al. · Molecular Cell · 2004 · 500 citations · Full text
DNA damage checkpoint control in cells exposed to ionizing radiation
George Iliakis, Ya Wang, Jun Guan et al. · Oncogene · 2003 · 475 citations